Parkinson's Disease Trial, Not Yet Recruiting NCT07611578 Sponsor: Alvaro Reyes Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Not Yet Recruiting

NCT07611578
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with idiopathic Parkinson's disease (a specific form of Parkinson's not caused by another condition) confirmed by a neurologist
  • People in Hoehn & Yahr stages I, II, or III (these are early to mid stages of Parkinson's disease — confirm with trial site if unsure which stage applies)
  • People with no cognitive difficulties, or only mild to moderate cognitive difficulties
  • People with or without symptoms of depression
  • People who are able to walk on their own without assistance
  • People whose Parkinson's medication type and dose has not changed in the three months before the study begins
  • People who are able to understand and follow the instructions given during the study

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have another neurological condition or a musculoskeletal (bone, joint, or muscle) condition alongside their Parkinson's disease
  • People with a history of injury or surgery involving the legs or brain
  • People who have vision or hearing problems that could affect their performance on thinking and memory tests
  • People who have been clinically diagnosed with a major neurocognitive disorder (a significant decline in memory and thinking abilities)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Alvaro Reyes
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 January 2029

Where this trial is recruiting

🇨🇱 Chile

Primary endpoints

Self-efficacy (The Latin Spanish version of the Self-Efficacy to Manage Chronic Disease for the Chilean population ); Self-efficacy (General Self-Efficacy Scale); Unified Parkinson's Disease Rating Scale (revised version); Balance; Gait (walking speed); Cognitive function; Brain activity of the Prefrontal cortex; Dual task cost; Difficulties associated with Parkinson's disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov